Skip to content

Medical emergency? What to do

U.S. clears new flu vaccine, progress made on another

3-RXPublished September 1, 20052 min read

Key points

  • U.S. health officials approved a new flu vaccine on Wednesday in hopes of bolstering supplies after last season's shortage, but said more work is needed before another supplier may be able to resume sales.
  • "Having more manufacturers of influenza vaccine licensed in the U.S., and having more vaccine dosages, is critical to public health," Health and Human Services Secretary Mike Leavitt said in a statement.
  • Last October, Emeryville, California-based Chiron's manufacturing license for its Fluvirin vaccine was withdrawn because of contamination at its factory in Liverpool, England.
  • While certain U.S. regions were temporarily left without vaccine, the season ended with a surplus of unused doses.

U.S. health officials approved a new flu vaccine on Wednesday in hopes of bolstering supplies after last season's shortage, but said more work is needed before another supplier may be able to resume sales.

The new vaccine, made by GlaxoSmithKline Plc, aims to fill the void left after rival Chiron Corp. lost its license and could not deliver half the anticipated U.S. supply during the 2004-2005 flu season.

"Having more manufacturers of influenza vaccine licensed in the U.S., and having more vaccine dosages, is critical to public health," Health and Human Services Secretary Mike Leavitt said in a statement.

The approval comes just weeks before the start of the 2005-2006 U.S. flu season, which officials hope will not repeat last year's scramble for the vaccine.

Last October, Emeryville, California-based Chiron's manufacturing license for its Fluvirin vaccine was withdrawn because of contamination at its factory in Liverpool, England.

The loss of the expected supply led to early confusion and long lines. Officials searched for alternative supplies from around the world and imported 4 million doses from Glaxo.

While certain U.S. regions were temporarily left without vaccine, the season ended with a surplus of unused doses.

"Previous shortages highlighted the need for additional influenza vaccine manufacturers for the U.S. market," Food and Drug Administration Commissioner Lester Crawford said.

Chiron on Wednesday said the FDA issued a favorable report following a July inspection of its Liverpool plant, finding the company's proposed corrections "generally acceptable."

The FDA said Chiron had made "significant progress" in fixing its problems, but added the agency will still need to give final approval before the vaccine can be sold.

"Additional work is needed to determine the amount of vaccine Chiron may be able to supply the U.S. market for the upcoming flu season," Dr. Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research, said.

Harris Nesbitt analyst Thomas Shrader said the favorable inspection was not a surprise and that he expected the FDA to approve Chiron's vaccine.

In the meantime, GlaxoSmithKline has said it plans to ramp up production of its vaccine, which was cleared for use in adults age 18 and older.

GlaxoSmithKline CEO Jean-Pierre Garnier said his company "worked quickly with government officials to make Fluarix available and increase supply at a critical time."

The British drugmaker will join the only other drugmaker cleared to sell the shots for the U.S. market, Sanofi-Aventis. MedImmune Inc. also makes a nasal spray vaccine.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.